Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Benuvia Operations and Chromocell Form Strategic Partnership for Healthcare Solutions
Details : The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : Diclofenac
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabidiol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Radius Health
Deal Size : $72.5 million
Deal Type : Acquisition
Radius Health, Inc. Announces Acquisition of Orphan Disease Program
Details : Radius Health has acquired the global development and commercialization rights to Benuvia Therapeutics' RAD011, a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases.
Brand Name : RAD011
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 06, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Radius Health
Deal Size : $72.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?